The FDA’s approval of the first at-home administration of a flu vaccine, specifically an intranasal version (FluMist), is a significant step in expanding access to preventive care. However, it's important to be cautious, as not everyone is a candidate for this type of flu vaccine.
FluMist, a live attenuated influenza vaccine (LAIV), has been available for more than 20 years, but the novelty here lies in its recent approval for home administration. As with any live vaccine, certain populations should avoid FluMist and opt for the traditional intradermal (injected) vaccines instead.
Those who should not use FluMist include:
- People with asthma: Since FluMist is administered intranasally, it can cause respiratory symptoms, which may exacerbate asthma.
- Individuals with compromised immune systems: People who are immunocompromised (due to conditions such as common variable immunodeficiency, specific antibody deficiency, cancer and HIV) should avoid live vaccines, as they may not be able to fight off even a weakened form of the virus.
- Children under 2 years old and adults over 50: FluMist is only recommended for healthy people aged 2 to 49 years.
- Pregnant individuals: They should stick to the inactivated flu vaccine (given as a shot).
- People with certain chronic conditions: Those with heart disease, lung disease (other than asthma), diabetes, and kidney or liver disorders should also avoid this vaccine unless otherwise directed by their healthcare provider.
For those outside these groups, at-home administration could offer a more convenient option for annual flu prevention, potentially increasing vaccine uptake.
Speak with your Atlanta Allergy & Asthma provider if you have any questions about flu prevention and other preventative care options specific to your diagnosis.